论文部分内容阅读
长久以来我们国家的科研与生产存在着不同程度的脱节,许多耗费巨资开发的技术无法投入应用,如何使众多科研成果走出实验室,进入产业化轨道成了一个重大问题。为能在这一领域闯出一条新路,第二军医大学医学生物技术和分子遗传研究所利用开发基因工程干扰素γ的下游技术的契机,在完成实验研究后建立了中试车间,并以此为基础与上海创新科技公司共同投资组建了上海克隆生物高技术有限公司,走上了以产业化作为发展方向,科研与生产并举的发展道路。公司投入250万元改建了800平方米符合制药GMP的厂房,并完善了制水等一系列辅助设施,购置了700多万元的生产科研仪器设备。为能使实验室开发与生产更紧密结合,建立了三个中试车间,以适合不同品种的开发需要。
For a long time, our country’s scientific research and production have been disjointed to varying degrees. Many technologies that are costly to develop have been unable to be put into use. How to get a lot of scientific research results out of laboratories and into the industrial track has become a major issue. In order to create a new path in this field, the Institute of Medical Biotechnology and Molecular Genetics of the Second Military Medical University took advantage of the downstream technology for the development of genetically engineered interferon gamma to establish a pilot plant after the completion of the experimental study. This is based on the joint investment with the Shanghai Innovation and Technology Corporation to establish Shanghai Clone Biotech Co., Ltd. and embarked on the development road of industrialization as the direction of development, scientific research and production. The company invested 2.5 million yuan to reconstruct 800 square meters of factories that meet the requirements of pharmaceutical GMP, and improved a series of auxiliary facilities such as water production, and purchased more than 7 million yuan of production and scientific research equipment. In order to enable the close integration of laboratory development and production, three pilot plants were established to suit the development needs of different species.